Online inquiry

IVTScrip™ mRNA-Anti-TNF, ABP 501(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1179MR)

This product GTTS-WQ1179MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets TNF gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000594.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7124
UniProt ID P01375
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNF, ABP 501(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ1179MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ11797MR IVTScrip™ mRNA-Anti-PDCD1, MK-3475(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MK-3475
GTTS-WQ12000MR IVTScrip™ mRNA-Anti-ERBB3, MM-121(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MM-121
GTTS-WQ7653MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN-1029(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GEN-1029
GTTS-WQ14636MR IVTScrip™ mRNA-Anti-DLL3, SC0001-SCX(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SC0001-SCX
GTTS-WQ14079MR IVTScrip™ mRNA-Anti-DLL4, REGN-421(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA REGN-421
GTTS-WQ11197MR IVTScrip™ mRNA-Anti-TNFRSF18, MEDI-1873(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI-1873
GTTS-WQ2568MR IVTScrip™ mRNA-Anti-IGF1R, AMG 479(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG 479
GTTS-WQ4837MR IVTScrip™ mRNA-Anti-SDC1, BT-062(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BT-062
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW